Providing advancements in hemodialysis treatment and options for treating intractable diseases through therapeutic apheresis.

Blood Purification

Utilizing over 50 years of manufacturing technology and expertise in the fields of blood purification therapy, we contribute to “advancements in hemodialysis treatment” and “providing therapeutic apheresis as new options for treating intractable diseases.” Since successfully developing hollow fiber dialysis membranes using our unique cellulose fiber technology in 1974, we have continued to innovate dialyzer technology, improve quality, and ensure stable product supply, gaining wide support both domestically and internationally. Additionally, based on our “membrane separation” and “adsorption separation” technologies, we have worked on the development of medical devices for therapeutic apheresis. In the late 1970s, we established plasma exchange technology for the treatment of fulminant hepatitis, which later evolved into plasma component separation and adsorption technology. Today, the medical devices utilizing these technologies are covered by insurance for over 30 diseases in Japan and are widely used overseas. Building on the technology and expertise we have accumulated and refined in the fields of blood purification therapy, we aim to achieve safer and more effective treatments and continue to address unresolved medical challenges, contributing to the health and future of healthcare.

Contributing to the resolution of diverse and complex challenges in intensive care through cutting-edge solutions in the world.

Intensive Care

Intensive care refers to advanced medical care provided to patients with severe illnesses or injuries to sustain life and promote recovery. In the Intensive Care Unit (ICU), comprehensive treatment utilizing advanced medical knowledge and equipment is provided 24/7 to protect patients’ lives. With the advancement of medical technology in recent years, survival rates have improved. However, new challenges beyond saving lives have also come into focus, such as improving the quality of life (QOL) of patients during hospitalization, ensuring smooth social reintegration after discharge, providing mental care for families, and reducing the burden on healthcare professionals.

Our intensive care business contributes to solving these diverse and complex challenges by providing essential treatment options based on our core technologies, as well as providing cutting-edge solutions from around the world. We aim to create new value, alleviating the “pain” experienced by patients, their families, and healthcare professionals, and becoming a bridge to a world where everyone can live “as themselves.”

Using Autologous
Blood and Improving
Safety and Quality of
Health care

Our autologous blood related business aim to contribute to safer and higher quality medical care by utilizing patients' autologous blood.
We offer automated device and kits for the production of completely autologous fibrin glue from autologous plasma, blood bag system for leukocyte removal before storage with autologous blood preservation fluid.
The automated device produces completely autologous fibrin glue from autologous plasma of the patient's own plasma, thus avoiding the risk of infection which could not be completely ruled out by the use of biological products.
The autologous blood storage kit product that combines a blood bag system for white blood cell removal with a blood storage solution improves the quality and safety of blood during autologous blood transfusion by removing white blood cells.